Blar i NTNU Open på forfatter "Frøen, Hege"

Viser treff 1-3 av 3

    • Cold agglutinin disease revisited: a multinational, observational study of 232 patients 

      Berentsen, Sigbjørn; Barcellini, Wilma; D'Sa, Shirley; Randen, Ulla; Tvedt, Tor Henrik Anderson; Fattizzo, Bruno; Haukås, Einar; Kell, Megan; Brudevold, Robert; Dahm, Anders Erik Astrup; Dalgaard, Jakob; Frøen, Hege; Hallstensen, Randi; Jæger, Pernille Horgmo; Hjorth-Hansen, Henrik; Malecka, Agnieszka Maria; Oksman, Markku; Rolke, Jürgen; Sekhar, Mallika; Sørbø, Jon Hjalmar; Tjønnfjord, Eirik; Tsykunova, Galina; Tjønnfjord, Geir Erland (Peer reviewed; Journal article, 2020)
      We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5 countries. In Norway and a northern region of Italy, the study was close to being population-based. For the first time, we ...

    • Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up 

      Larsen, Trine-Lise; Garresori, Herish; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege; Jacobsen, Eva-Marie; Quist-Paulsen, Petter; Porojnicu, Alina Carmen; Ree, Anne Hansen; Torfoss, Dag; Velle, Elin Osvik; Wik, Hilde Skuterud; Ghanima, Waleed; Sandset, Per Morten; Dahm, Anders Erik A (Peer reviewed; Journal article, 2022)
      Background - There are no data on the effect of low‐dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low‐dose apixaban for 30 months, ...

    • Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism 

      Hannevik, Trine-Lise; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege; Ahmed, Herish; Jacobsen, Eva-Marie; Quist-Paulsen, Petter; Porojnicu, Alina Carmen; Ree, Anne Hansen; Torfoss, Dag; Velle, Elin Osvik; Wik, Hilde Skuterud; Ghanima, Waleed Khalid; Sandset, Per Morten; Dahm, Anders Erik A (Peer reviewed; Journal article, 2020)
      Introduction: The direct oral anti-coagulants (DOAC) edoxaban and rivaroxaban are suggested treatment alternatives for cancer-associated venous thromboembolism (VTE) together with low molecular-weight heparins. New studies ...